Form 4: Arcutis Biotherapeutics Executive Sells Shares After Performance Stock Units Vest
SEC Form 4 Filing
Arcutis Biotherapeutics' Senior Vice President, Masaru Matsuda, sold shares to cover tax obligations after performance stock units vested.
Summary
- Masaru Matsuda, a Senior Vice President at Arcutis Biotherapeutics, acquired 4,875 shares of common stock on November 18, 2024, due to the vesting of performance stock units (PSUs).
- These PSUs were initially granted on January 3, 2022, and vested based on a performance condition certified on November 18, 2022.
- The PSUs vest 25% per year on each anniversary of the certification date, contingent on continued service.
- On November 19, 2024, Mr. Matsuda sold 1,775 shares at a weighted average price of $9.6847 per share to cover tax withholdings related to the vesting.
- The sale price ranged from $9.22 to $10.09 per share.
- Following these transactions, Mr. Matsuda beneficially owns 181,373 shares of Arcutis Biotherapeutics common stock.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction related to executive compensation. There is no indication of any negative or positive sentiment, it is a standard process.
Industry Context
This is a routine transaction related to executive compensation and is common in publicly traded companies. The sale of shares to cover tax obligations is a standard practice.
Comparison to Industry Standards
- The vesting of performance-based stock units and subsequent sale to cover taxes is a common practice among publicly traded companies, particularly in the biotech sector.
- Many companies use similar vesting schedules, often with annual vesting over a period of years, contingent on continued employment and performance metrics.
- The sale of shares to cover tax obligations is a standard procedure to avoid executives having to pay tax out of pocket.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves a small number of shares being sold by an executive.
- The sale is a standard part of executive compensation and does not indicate any change in the company's outlook.
Key Dates
| Date | Description |
|---|---|
| 01/03/2022 | Initial grant date of performance stock units. |
| 11/18/2022 | Certification date of the performance-based vesting condition. |
| 11/18/2024 | Vesting date of performance stock units resulting in acquisition of shares. |
| 11/19/2024 | Date of share sale to cover tax withholdings. |
Keywords
Arcutis Biotherapeutics, stock units, share sale, insider trading, performance stock units, vesting, tax withholdings, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.